Monday, April 30, 2012

Actelion's Macitentan Meets Primary Endpoint in Pivotal Phase III Seraphin Outcome Study in patients with pulmonary arterial hypertension

(Reuters) - Actelion announced today that initial analysis indicates that the pivotal, long-term, event-driven study SERAPHIN with macitentan, a novel dual endothelin receptor antagonist, in 742 patients suffering from pulmonary arterial hypertension (PAH) and treated for up to three and a half years, has met its primary endpoint. Read article

No comments: